Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. (linkinghub.elsevier.com)

Authors: Rosenstock J … Zhao Y Journal: The Lancet Published: 2026-03-21 DOI: https://doi.org/10.1016/S0140-6736(26)00202-3